Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
3,799
Views
4
CrossRef citations to date
0
Altmetric
Oncology
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective
Tobias Engel Ayer Botrela CIOP – Centro Integrado de Oncologia e Pesquisa, Poços de Caldas, Brazil
https://orcid.org/0000-0001-9137-0637
Márcia Datz Abadib MSD Brasil, São Paulo, Brazil
, Laura Chabrol Haasb MSD Brasil, São Paulo, Brazil
, Cássia Rita Pereira da Veigab MSD Brasil, São Paulo, Brazil;c Department of General and Applied Administration, Universidade Federal do Paraná, Curitiba, BrazilCorrespondence[email protected]
https://orcid.org/0000-0002-9219-6279
Dominihemberg de Vasconcelos Ferreirab MSD Brasil, São Paulo, Brazil
& Denis Leonardo Jardimd Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil
https://orcid.org/0000-0003-4663-1521
Pages 291-298
|
Received 06 Oct 2020, Accepted 26 Jan 2021, Published online: 01 Mar 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.